Form 4: Delcath Systems Executive Acquires Stock Options
SEC Form 4 Filing
Kevin Muir, GM of Interventional Oncology at Delcath Systems, acquired 113,000 stock options on February 7, 2025.
Summary
- Kevin Muir, General Manager of Interventional Oncology at Delcath Systems, Inc., filed a Form 4.
- On February 7, 2025, Muir acquired 113,000 stock options with an exercise price of $16.25.
- The options vest monthly over three years, starting February 7, 2025, contingent on continued employment.
- The options expire on February 7, 2035.
- Following the transaction, Muir directly owns 113,000 derivative securities.
Sentiment
Score: 7
Explanation: The granting of stock options to a key executive is generally a positive sign, indicating confidence in the company's future prospects and aligning management's interests with those of shareholders.
Positives
- The acquisition of stock options by a key executive signals confidence in the company's future performance.
Industry Context
This is a standard practice for incentivizing key employees in publicly traded companies.
Stakeholder Impact
- The granting of stock options aligns the interests of the executive with those of the shareholders, potentially leading to increased shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of the transaction and first vesting date of the stock options. |
| 02/07/2035 | Expiration date of the stock options. |
Keywords
stock options, Delcath Systems, Form 4, executive compensation, beneficial ownership, Muir, DCTH
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.